Replies to post #203180 on Biotech Values

[DewDiligence]

BMY—...on recent investor calls it's sounded like they were conducting a hierarchical analysis that would have started at higher cutoffs.

I listened to all the recent calls and didn't get that impression; rather, I was unable to infer what the primary endpoint was, and I thought BMY was playing its cards unduly close to the vest for reasons that weren't entirely clear.

[dewophile]

outcomes at higher levels of expression of pd-1 ligand were prespecified, and I agree this could be a short term hit if combos pan out (i think yervoy combo is a long shot, but chemo combo is likely to be superior to pd-1 alone - JMO)
yes so odd to see a negative outcome w a PD-1